These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16467761)

  • 41. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
    Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
    Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitomycin C from birth to adulthood.
    Serretta V; Scalici Gesolfo C; Alonge V; Di Maida F; Caruana G
    Urologia; 2016 Oct; 83(Suppl 2):2-6. PubMed ID: 27716885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
    Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
    Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Mostafid AH; Rajkumar RG; Stewart AB; Singh R
    BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study.
    Brausi M; Campo B; Pizzocaro G; Rigatti P; Parma A; Mazza G; Vicini A; Stephen RL
    Urology; 1998 Mar; 51(3):506-9. PubMed ID: 9510365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
    Krege S; Giani G; Meyer R; Otto T; Rübben H
    J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.
    Cheng CW; Chan PS; Chan LW; Chan CK; Ng CF; Lai MM
    Int Braz J Urol; 2005; 31(3):204-11. PubMed ID: 15992422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short schedule intravesical mitomycin preceding transurethral resection for recurrent Ta-T1, G1-G2 bladder cancer.
    Maffezzini M; Simonato A; Lodolo C; Raber M; Carmignani G
    Tumori; 1995; 81(3):191-3. PubMed ID: 7571026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: long-term results.
    Hurle R; Manzetti A; Losa A; Micheli E; Ranieri A; Chinaglia D; Lembo A
    Urol Int; 1998; 61(4):220-6. PubMed ID: 10364753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
    da Silva FC; Ferrito F; Brandão T; Santos A
    Eur Urol; 1992; 21(1):42-4. PubMed ID: 1606981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial.
    De Nunzio C; Carbone A; Albisinni S; Alpi G; Cantiani A; Liberti M; Tubaro A; Iori F
    World J Urol; 2011 Aug; 29(4):517-21. PubMed ID: 21594708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapeutic effect of mitomycin C in the immediate postoperative period in patients with intermediate-risk non-muscle-invasive bladder tumors].
    Jalón Monzón A; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Martín Benito JL; Regadera Sejas FJ
    Actas Urol Esp; 2008 Oct; 32(9):894-903. PubMed ID: 19044299
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
    Schwaibold H; Pichlmeier U; Klingenberger HJ; Huland H
    Eur Urol; 1997; 31(2):153-9. PubMed ID: 9076457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection.
    Ba M; Cui S; Wang B; Long H; Yan Z; Wang S; Wu Y; Gong Y
    Oncol Rep; 2017 May; 37(5):2761-2770. PubMed ID: 28405683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
    Li NC; Ye ZQ; Na YQ;
    Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.